News

Celebrating the Appointment of Professor Miranda Stewart at IBFD

Celebrating the Appointment of Professor Miranda Stewart at IBFD

Announcing Professor Miranda Stewart as IBFD's New Global Scholar

We are delighted to share the news that Professor Miranda Stewart has been appointed as the Visiting Global Scholar at IBFD for the period of 2026 and 2027. Professor Stewart is a highly respected expert with extensive knowledge in tax law and contributes her expertise as a Professor at the University of Melbourne Law School while also serving as a Visiting Professor at New York University School of Law.

The Role and Impact of a Visiting Global Scholar

Beginning in 2026, the Visiting Global Scholar program at IBFD invites distinguished academics to engage deeply with the institute's activities over two years. This initiative fosters collaboration between IBFD and leading scholars, enhancing research projects and promoting significant participation in academic events. The continuation of this collaboration is expected to lead to enriched knowledge dissemination and impactful research contributions.

Why Professor Stewart Stands Out

As a scholar, Miranda Stewart is known for her ability to merge tax law with a comprehensive understanding of global taxation policies. Her unique perspective is valued highly, especially by IBFD's Academic Chairman, Professor Dr. Pasquale Pistone, who acknowledges her as a world-class scholar. He states that her partnership will significantly elevate IBFD's research capabilities in various pertinent tax-related discussions.

Exciting Contributions Ahead

Professor Stewart expressed her enthusiasm about joining IBFD, emphasizing her participation in the upcoming IBFD Academic Conference. This conference will delve into fundamental taxation issues, like the Ability to Pay, aligning with her ongoing research interests. She is set to collaborate with the academic research team on critical international tax topics, including framework discussions with the United Nations.

About Professor Miranda Stewart

Miranda Stewart’s academic credentials are impressive, as she holds a position at the University of Melbourne and contributes to the global educational landscape as the Faculty Director of the International Tax LLM program at NYU. Additionally, she is an Honorary Professor at the Crawford School of Public Policy at the Australian National University and has provided advisory services to various governments and international bodies, including the Australian Treasury and the International Monetary Fund.

Her research covers a multitude of topics in international and domestic tax law, reinforcing her reputation in the field. Miranda Stewart's recent publication, Tax and Government in the 21st Century, showcases her expertise and has garnered recognition, enhancing her credentials even further.

Understanding the Visiting Global Scholar Initiative

Since its inception in 2013, the Visiting Global Scholar initiative has brought numerous distinguished figures to IBFD, allowing for rich exchanges of ideas and research collaborations. This two-year appointment not only benefits the institution but also enhances the overall academic environment with fresh perspectives and innovative research agendas.

Significance of the Scholar’s Role

The Visiting Global Scholar plays an active role in teaching and research, contributing to knowledge-sharing in the field of tax law. Their tenure supports rigorous scientific work and ensures worldwide exposure through various platforms, including Distinguished Lectures that help in the evolution of tax law research.

About IBFD: The Leading Tax Expertise Provider

IBFD stands at the forefront of cross-border tax research, operating as an independent, non-profit entity with a rich history spanning multiple decades. By leveraging an extensive network of tax professionals, IBFD caters to a diverse clientele that includes Fortune 500 companies, governments, and educational institutions.

Research, publishing, and education in international taxation form the core of IBFD’s mission, delivering valuable resources through its Tax Research Platform, ensuring effective access to essential tax information. Established in 1938 and located in Amsterdam, IBFD is committed to expanding its reach and influence across significant global markets.

Frequently Asked Questions

What is the role of Professor Miranda Stewart at IBFD?

Professor Stewart is the Visiting Global Scholar for IBFD for the years 2026/2027, focusing on collaboration and research in international taxation.

What does the Visiting Global Scholar initiative entail?

This program invites distinguished scholars to engage at IBFD for two years, enhancing teaching and research in tax law.

How does Professor Stewart contribute to IBFD?

She will lead research on international tax topics, participate in academic conferences, and deliver lectures during her tenure.

What is IBFD's primary mission?

IBFD aims to provide cross-border tax expertise through research, publishing, and education to enhance global tax understanding.

How has IBFD influenced tax research?

IBFD utilizes a global network of experts to produce valuable insights and resources, supporting various organizations in navigating tax complexities.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 190

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 230

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 144

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading
Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 242

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
LexisNexis Debuts AI-Guided Field Clarity at IACP 2026

Updated Category News Views 59

LexisNexis Takes a Serious Step Forward The world of law enforcement reporting just got a shake-up. LexisNexis Coplogic Solutions launched a souped-up version of its Desk Officer Reporting System (DORS) at the IACP 2026 event. They paired DORS with Field Clarity, a newfangled AI-powered assistant that aims to make police reporting slicker and more accurate. You can bet...

Continue Reading
RYBREVANT's Promising Results in HNSCC Treatment

Updated Category News Views 80

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Continue Reading
Survivors Secure $800M Settlement with NY Archdiocese

Updated Category News Views 299

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 242

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event

Updated Category News Views 96

Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...

Continue Reading
Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 104

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading

Top 5 Most Recently Viewed Articles

Macao's 25-Year Journey: Celebrating Growth and Prosperity

Updated Category News Views 161

Macao's Remarkable Development Over 25 Years In a vibrant celebration of progress, Macao recently marked the significant milestone of its 25th anniversary since its return to the motherland. A special publication by an English-language newspaper highlighted various achievements that the region has made during this transformative period. Economic Growth and Transformation...

Continue Reading
Opportunity to Address Losses: Join Tempus AI Class Action

Updated Category News Views 128

Investors Encouraged to Participate in Tempus AI Class Action The law firm Robbins Geller Rudman & Dowd LLP is actively reaching out to investors of Tempus AI, Inc. (NASDAQ: TEM) who have experienced notable financial losses. They have announced an opportunity for eligible investors to take the lead in an associated class action lawsuit. This potential action stems from...

Continue Reading
Muncy Columbia Financial Corporation's Strong Q4 2024 Earnings

Updated Category News Views 99

Muncy Columbia Financial Corporation's Financial Outlook Muncy Columbia Financial Corporation (“Corporation”) (OTCQX: CCFN), after releasing its unaudited consolidated financial statements for the fourth quarter of 2024, has demonstrated significant improvement over the previous year. Fourth Quarter 2024 Financial Highlights For the quarter ending December 31, 2024,...

Continue Reading
Caris Life Sciences Expands Cancer Research Alliance

Updated Category News Views 119

Caris Life Sciences Expands Cancer Research Alliance Caris Life Sciences® (NASDAQ: CAI), a forefront player in precision medicine and next-generation AI TechBio, is excited to share the arrival of Providence Swedish Cancer Institute into the esteemed Caris Precision Oncology Alliance (Caris POA). This addition enhances their collective mission to revolutionize cancer...

Continue Reading
Zumiez Inc. Gears Up for First Quarter 2025 Financial Report

Updated Category News Views 263

Upcoming Financial Report for Zumiez Inc. Zumiez Inc. (NASDAQ: ZUMZ) has recently made an exciting announcement regarding its financial performance. The company is set to release its first quarter results for fiscal 2025 on June 5, after the stock market closes. This pivotal moment is eagerly anticipated by investors and stakeholders alike, as it will provide valuable...

Continue Reading